Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aziz Nazha

Showing results (91-100 of 121) with videos related to

Pageof 13
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|August 10, 2014
Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemiaNaveen Pemmaraju, Dhaval Shah, Hagop Kantarjian, et al.
Blood Advances|February 3, 2019
Invariant phenotype and molecular association of biallelic <i>TET2</i> mutant myeloid neoplasiaHassan Awada, Yasunobu Nagata, Abhinav Goyal, et al.
American Journal of Hematology|July 28, 2018
Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-RChristopher B Benton, Maliha Khan, David Sallman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2019
A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid LeukemiaAnjali S Advani, Brenda Cooper, Valeria Visconte, et al.
Blood|June 2, 2021
Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemiaHassan Awada, Arda Durmaz, Carmelo Gurnari, et al.
Nature Communications|November 28, 2019
Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromesYasunobu Nagata, Hideki Makishima, Cassandra M Kerr, et al.
Blood|September 23, 2018
Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiablePrithviraj Bose, Aziz Nazha, Rami S Komrokji, et al.
Blood Advances|September 30, 2021
A geno-clinical decision model for the diagnosis of myelodysplastic syndromesNathan Radakovich, Manja Meggendorfer, Luca Malcovati, et al.
Blood Neoplasia|June 2, 2025
Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trialTimothy S Pardee, Bayard L Powell, Richard A Larson, et al.
Leukemia & Lymphoma|November 3, 2020
Analysis of distinct <i>SF3B1</i> hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasiaVera Adema, Jack Khouri, Ying Ni, et al.
Pageof 13

Showing results (91-100 of 121) with videos related to

Sort By:
Pageof 13
Clinical Lymphoma, Myeloma & Leukemia|August 10, 2014
Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemiaNaveen Pemmaraju, Dhaval Shah, Hagop Kantarjian, et al.
Blood Advances|February 3, 2019
Invariant phenotype and molecular association of biallelic <i>TET2</i> mutant myeloid neoplasiaHassan Awada, Yasunobu Nagata, Abhinav Goyal, et al.
American Journal of Hematology|July 28, 2018
Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-RChristopher B Benton, Maliha Khan, David Sallman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2019
A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid LeukemiaAnjali S Advani, Brenda Cooper, Valeria Visconte, et al.
Blood|June 2, 2021
Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemiaHassan Awada, Arda Durmaz, Carmelo Gurnari, et al.
Nature Communications|November 28, 2019
Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromesYasunobu Nagata, Hideki Makishima, Cassandra M Kerr, et al.
Blood|September 23, 2018
Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiablePrithviraj Bose, Aziz Nazha, Rami S Komrokji, et al.
Blood Advances|September 30, 2021
A geno-clinical decision model for the diagnosis of myelodysplastic syndromesNathan Radakovich, Manja Meggendorfer, Luca Malcovati, et al.
Blood Neoplasia|June 2, 2025
Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trialTimothy S Pardee, Bayard L Powell, Richard A Larson, et al.
Leukemia & Lymphoma|November 3, 2020
Analysis of distinct <i>SF3B1</i> hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasiaVera Adema, Jack Khouri, Ying Ni, et al.
Pageof 13